Regulation of mitochondrial oxidative metabolism by tumor suppressor FLCN

Journal of the National Cancer Institute

Volumn 104, Issue 22, 2012, Pages 1750-1764

  Hasumi, Hisashi ^a   Baba, Masaya ^a   Hasumi, Yukiko ^a   Huang, Ying ^a   Oh, Hyoungbin ^a   Hughes, Robert M ^a   Klein, Mara E ^a   Takikita, Shoichi ^b   Nagashima, Kunio ^c,d   Schmidt, Laura S ^a,d   Linehan, W Marston ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b National Institute of Arthritis Musculoskeletal and Skin Diseases   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; CADHERIN 16; CREATINE KINASE MM; MYOGENIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN FLCN; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ALLELE; ANIMAL EXPERIMENT; ARTICLE; ASSAY; BIOGENESIS; CANCER CELL CULTURE; CONTROLLED STUDY; ELECTRON MICROSCOPY; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; KIDNEY CANCER; KIDNEY CELL CULTURE; METABOLIC PROFILING ASSAY; MITOCHONDRIAL OXIDATIVE METABOLISM; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRANSGENE;

ANIMALS; BIRT-HOGG-DUBE SYNDROME; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, KNOCKOUT; MICROSCOPY, ELECTRON; MITOCHONDRIA; MITOCHONDRIAL TURNOVER; MUSCLES; OXIDATION-REDUCTION; OXYGEN CONSUMPTION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84870204290     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs418     Document Type: Article

References (60)

1. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010;7(5):277-285.
2. Linehan WM, Pinto PA, Srinivasan R, et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res. 2007;13(2 Pt 2):671s-679s.
3. Baba M, Furihata M, Hong SB, et al. Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst. 2008;100(2):140-154. (Pubitemid 351480566)
4. Hasumi Y, Baba M, Ajima R, et al. Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci U S A. 2009; 106(44):18722-18727.
5. Nickerson ML, Warren MB, Toro JR, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell. 2002;2(2):157-164. (Pubitemid 41039116)
6. Vocke CD, Yang Y, Pavlovich CP, et al. High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dube-associated renal tumors. J Natl Cancer Inst. 2005;97(12):931-935. (Pubitemid 41417945)
7. Baba M, Hong SB, Sharma N, et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A. 2006;103(42):15552-15557. (Pubitemid 44625630)
8. Hasumi H, Baba M, Hong SB, et al. Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene. 2008;415(1-2):60-67.
9. Takagi Y, Kobayashi T, Shiono M, et al. Interaction of folliculin (Birt- Hogg-Dube gene product) with a novel Fnip1-like (FnipL/Fnip2) protein. Oncogene. 2008;27(40):5339-5347.
10. Cash TP, Gruber JJ, Hartman TR, Henske EP, Simon MC. Loss of the Birt- Hogg-Dube tumor suppressor results in apoptotic resistance due to aberrant TGFbeta-mediated transcription. Oncogene. 2011;30(22):2534-2546.
11. Hartman TR, Nicolas E, Klein-Szanto A, et al. The role of the Birt-Hogg- Dube protein in mTOR activation and renal tumorigenesis. Oncogene. 2009;28(13):1594-1604.
12. Hudon V, Sabourin S, Dydensborg AB, et al. Renal tumour suppressor function of the Birt-Hogg-Dube syndrome gene product folliculin. J Med Genet. 2010;47(3):182-189.
13. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet. 2005;37(1):19-24. (Pubitemid 40070934)
14. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell. 2004;6(1):91-99. (Pubitemid 38903165)
15. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345-1356.
16. Goncharova EA, Goncharov DA, Li H, et al. mTORC2 is required for proliferation and survival of TSC2-null cells. Mol Cell Biol. 2011;31(12):2484-2498.
17. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 2009;23(5):537-548.
18. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-1033.
19. Yeung RS. Multiple roles of the tuberous sclerosis complex genes. Genes Chromosomes Cancer. 2003;38(4):368-375. (Pubitemid 37466938)
20. Singh SR, Zhen W, Zheng Z, et al. The Drosophila homolog of the human tumor suppressor gene BHD interacts with the JAK-STAT and Dpp signaling pathways in regulating male germline stem cell maintenance. Oncogene. 2006;25(44):5933-5941. (Pubitemid 44477287)
21. Hong SB, Oh H, Valera VA, et al. Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling. Mol Cancer. 2010;9:160.
22. Hong SB, Oh H, Valera VA, Baba M, Schmidt LS, Linehan WM. Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization. PLoS One. 2010;5(12):e15793.
23. Handschin C, Chin S, Li P, et al. Skeletal muscle fiber-type switching, exercise intolerance, and myopathy in PGC-1alpha muscle-specific knockout animals. J Biol Chem. 2007;282(41):30014-30021. (Pubitemid 350035265)
24. Li S, Czubryt MP, McAnally J, et al. Requirement for serum response factor for skeletal muscle growth and maturation revealed by tissue-specific gene deletion in mice. Proc Natl Acad Sci U S A. 2005;102(4):1082-1087. (Pubitemid 40170729)
25. Bhattacharya SK, Thakar JH, Johnson PL, Shanklin DR. Isolation of skeletal muscle mitochondria from hamsters using an ionic medium containing ethylenediaminetetraacetic acid and nagarse. Anal Biochem. 1991;192(2):344-349.
26. Arany Z, Lebrasseur N, Morris C, et al. The transcriptional coactivator PGC-1beta drives the formation of oxidative type IIX fibers in skeletal muscle. Cell Metab. 2007;5(1):35-46. (Pubitemid 44939399)
27. Lin J, Wu H, Tarr PT, et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature. 2002;418(6899):797- 801.
28. Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature. 2007;450(7170):736-740. (Pubitemid 350207689)
29. Arany Z, He H, Lin J, et al. Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab. 2005;1(4):259-271. (Pubitemid 43960608)
30. Fernandez-Marcos PJ, Auwerx J. Regulation of PGC-1alpha, a nodal regulator of mitochondrial biogenesis. Am J Clin Nutr. 2011; 93(4):884S-890.
31. Handschin C, Chin S, Li P, et al. Skeletal muscle fiber-type switching, exercise intolerance, and myopathy in PGC-1alpha muscle-specific knockout animals. J Biol Chem. 2007;282(41):30014-30021. (Pubitemid 350035265)
32. Lin J, Wu PH, Tarr PT, Lindenberg KS, St-Pierre J, Zhang CY et al. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell. 2004;119(1):121-135. (Pubitemid 39349325)
33. Michael LF, Wu Z, Cheatham RB, et al. Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc Natl Acad Sci U S A. 2001;98(7):3820-3825. (Pubitemid 32249855)
34. Wu Z, Puigserver P, Andersson U, et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell. 1999;98(1):115-124. (Pubitemid 29331201)
35. Puigserver P, Rhee J, Lin J, et al. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. Mol Cell. 2001;8(5):971-982. (Pubitemid 34031800)
36. Spiegelman BM. Transcriptional control of mitochondrial energy metabolism through the PGC1 coactivators. Novartis Found Symp. 2007;287:60-69.
37. St-Pierre J, Lin J, Krauss S, et al. Bioenergetic analysis of peroxisome proliferator-activated receptor gamma coactivators 1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells. J Biol Chem. 2003;278(29):26597-26603. (Pubitemid 36876804)
38. Bhalla K, Hwang BJ, Dewi RE, et al. PGC1alpha promotes tumor growth by inducing gene expression programs supporting lipogenesis. Cancer Res. 2011;71(21):6888-6898.
39. Shiota M, Yokomizo A, Tada Y, et al. Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR. Mol Endocrinol. 2010;24(1):114-127.
40. D'Errico I, Salvatore L, Murzilli S, et al. Peroxisome proliferatoractivated receptor-gamma coactivator 1-alpha (PGC1alpha) is a metabolic regulator of intestinal epithelial cell fate. Proc Natl Acad Sci U S A. 2011;108(16):6603-6608.
41. St-Pierre J, Drori S, Uldry M, et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell. 2006;127(2):397-408. (Pubitemid 44572377)
42. Arany Z, Foo SY, Ma Y, et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature. 2008;451(7181):1008-1012. (Pubitemid 351301733)
43. Wu J, Ruas JL, Estall JL, et al. The unfolded protein response mediates adaptation to exercise in skeletal muscle through a PGC-1alpha/ATF6alpha complex. Cell Metab. 2011;13(2):160-169.
44. Preston RS, Philp A, Claessens T, et al. Absence of the Birt-Hogg- Dube gene product is associated with increased hypoxia-inducible factor transcriptional activity and a loss of metabolic flexibility. Oncogene. 2011;30(10):1159-1173.
45. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274-293.
46. Klomp JA, Petillo D, Niemi NM, et al. Birt-Hogg-Dube renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression. BMC Med Genomics. 2010;3:59.
47. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8(6):519-530.
48. Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309- 314.
49. Kuroda N, Toi M, Hiroi M, Shuin T, Enzan H. Review of renal oncocytoma with focus on clinical and pathobiological aspects. Histol Histopathol. 2003;18(3):935-942. (Pubitemid 36773237)
50. Moreno SM, Benitez IA, Martinez Gonzalez MA. Ultrastructural studies in a series of 18 cases of chromophobe renal cell carcinoma. Ultrastruct Pathol. 2005;29(5):377-387. (Pubitemid 41577217)
51. Nagashima Y, Mitsuya T, Shioi KI, et al. Renal oncocytosis. Pathol Int. 2005;55(4):210-5. (Pubitemid 40676931)
52. Higgins JP, Shinghal R, Gill H, et al. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol. 2003;162(3):925-932. (Pubitemid 36237499)
53. Osunkoya AO, Yin-Goen Q, Phan JH, et al. Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis. Hum Pathol. 2009;40(12):1671-1678.
54. Schuetz AN, Yin-Goen Q, Amin MB, et al. Molecular classification of renal tumors by gene expression profiling. J Mol Diagn. 2005;7(2):206-218. (Pubitemid 40668303)
55. Takahashi M, Yang XJ, Sugimura J, et al. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene. 2003;22(43):6810-6818. (Pubitemid 37372221)
56. Young AN, Amin MB, Moreno CS, et al. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol. 2001;158(5):1639-1651. (Pubitemid 32422929)
57. Mayr JA, Meierhofer D, Zimmermann F, et al. Loss of complex I due to mitochondrial DNA mutations in renal oncocytoma. Clin Cancer Res. 2008;14(8):2270-2275. (Pubitemid 351551057)
58. Gasparre G, Hervouet E, de Laplanche E, et al. Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I deficiency in the benign renal oncocytoma. Hum Mol Genet. 2008;17(7):986-995. (Pubitemid 351426033)
59. Kovacs A, Storkel S, Thoenes W, Kovacs G. Mitochondrial and chromosomal DNA alterations in human chromophobe renal cell carcinomas. J Pathol. 1992;167(3):273-277.
60. Welter C, Kovacs G, Seitz G, Blin N. Alteration of mitochondrial DNA in human oncocytomas. Genes Chromosomes Cancer. 1989;1(1):79-82. (Pubitemid 20093342)